DIFFERENTIAL DIAGNOSTIC TECHNIQUE FOR CEREBRAL GROWTHS Russian patent published in 2014 - IPC G01N33/52 

FIELD: medicine.

SUBSTANCE: method is implemented by IR spectroscopy of a patient's blood sample in the absorption spectrum range of 1,200-1,000 cm^-1; that is ensured by preparing the patient's dry blood serum sample by drying blood serum, milling a dry residue and suspending in Vaseline oil; a peak height of the absorption bands with maxima 1,170; 1,165; 1,160; 1,150; 1,140; 1,130; 1,125; 1,100; 1,070; 1,050 and 1,025 cm^-1, and peak height relations are calculated: the relation of the peak height at maximum 1,170 cm^-1 to the peak height at maximum 1,150 cm^-1; the relation of the peak height at maximum 1,165 cm^-1 to the peak height at maximum 1,160 cm^-1; the relation of the peak height at maximum 1,165 cm^-1 to the peak height at maximum 1,130 cm^-1, the relation of the peak height at maximum 1,165 cm^-1 to the peak height at maximum 1,070 cm^-1, the relation of the peak height at maximum 1,165 cm^-1 to the peak height at maximum 1,150 cm^-1, the relation of the peak height at maximum 1,165 cm^-1 to the peak height at maximum 1,140 cm^-1, the relation of the peak height at maximum 1,040 cm^-1 to the peak height at maximum 1,070 cm^-1, the relation of the peak height at maximum 1,070 cm^-1 to the peak height at maximum 1,025 cm^-1, the relation of the peak height at maximum 1,165 cm^-1 to the peak height at maximum 1,050 cm^-1, the relation of the peak height at maximum 1,165 cm^-1 to the peak height at maximum 1,025 cm^-1, the relation of the peak height at maximum 1,100 cm^-1 to the peak height at maximum 1,050 cm^-1, the relation of the peak height at maximum 1,170 cm^-1 to the peak height at maximum 1,160 cm^-1, the relation of the peak height at maximum 1,125 cm^-1 to the peak height at maximum 1,165 cm^-1; the derived values are used to draw a differential diagnostic profile of the patient's blood serum sample; that is ensured by plotting the derived relations on 13 corresponding radial beams outgoing from the centre (0:0 in the coordinate system) and inclined at 30°, each of which describes the certain relation of the peak heights of the absorption bands so that: beam 1 describes the relation of the absorption bands at 1,165/1,160, beam 2 - the relation of the absorption bands at 1,165/1,070, beam 3 - the relation of the absorption bands at 1,165/1,150, beam 4 - the relation of the absorption bands at 1,165/1,140, beam 5 - the relation of the absorption bands at 1,040/1,070, beam 6 - the relation of the absorption bands at 1,165/1,130, beam 7 - the relation of the absorption bands at 1,070/1,025, beam 8 - the relation of the absorption bands at 1,165/1,050, beam 9 - the relation of the absorption bands at 1,165/1,025, beam 10 - the relation of the absorption bands at 1,100/1,050, beam 11 - the relation of the absorption bands at 1,170/1,150, beam 12 - the relation of the absorption bands at 1,170/1,160, beam 13 - the relation of the absorption bands at 1,125/1,165; a plane polygon is formed by connecting the segment ends and compared to the polygons which are reference differential diagnostic profiles of cerebral malignant growth, such as: anaplastic astrocytoma, glioblastoma, anaplastic oligodendroastrocytoma, and benign growth, such as: ependymoma, meningioma, pituitary adenoma, neurinoma; for anaplastic astrocytoma, the 13 relations are as follows: 1 (0.56±0.07), 2 (0.54±0.06), 3 (0.42±0.05), 4 (0.39±0.02), 5 (1.34±0.16), 6 (0.73±0.17), 7 (0.72±0.12), 8 (0.44±0.01), 9 (0.38±0.08), 10 (0.27±0.12), 11 (0.15±0.05), 12 (0.20±0.07), 13 (0.97±0.17), for glioblastoma: 1 (0.83±0.04), 2 (1.16±0.12), 3 (0.62±0.01), 4 (0.63±0.04), 5 (1.26±0.21), 6 (1.26±0.13), 7 (0.73±0.12), 8 (0.96±0.13), 9 (1.13±0.01), 10 (0.27±0.13), 11 (0.34±0.04), 12 (0.34±0.14), 13 (0.57±0.18), for anaplastic oligodendroastrocytoma: 1 (0.50±0.02), 2 (0.50±0.05), 3 (0.50±0.02), 4 (0.50±0.02), 5 (1.14±0.03), 6 (1.44±0.04), 7 (0.75±0.01), 8 (0.41±0.06), 9 (0.37±0.03), 10 (0.33±0.04), 11 (0.17±0.04), 12 (0.16±0.03), 13 (0.46±0.03), for epenymoma: 1 (0.38±0.03), 2 (0.15±0.04), 3 (0.26±0.09), 4 (0.25±0.07), 5 (1.16±0.07), 6 (0.30±0.03), 7 (0.86±0.01), 8 (0.12±0.03), 9 (0.12±0.02), 10 (0.41±0.01), 11 (0.14±0.02), 12 (0.20±0.01), 13 (2.50±0.70), meningioma: 1 (0.40±0.03), 2 (0.35±0.03), 3 (0.37±0.01), 4 (0.35±0.01), 5 (1.07±0.01), 6 (0.54±0.01), 7 (0.93±0.03), 8 (0.34±0.01), 9 (0.32±0.01), 10 (0.40±0.01), 11 (0.12±0.02), 12 (0.13±0.01), 13 (1.13±0.05), for pituitary adenoma: 1 (0,45±0,05), 2 (0,34±0,04), 3 (0,41±0,03), 4 (0,56±0,03), 5 (1,05±0,02), 6 (0,60±0,05), 7 (0,94±0,04), 8 (0,30±0,03), 9 (0,32±0,03), 10 (0,48±0,01), 11 (0,12±0,04), 12 (0,13±0,05), 13 (1,05±0.03), for neurinoma: 1 (0.53±0.01), 2 (0.35±0.05), 3 (0.48±0.01), 4 (0.53±0.01), 5 (0.85±0.07), 6 (0.90±0.08), 7 (1.28±0.09), 8 (0.40±0.01), 9 (0.45±0.02), 10 (0.52±0.03), 11 (0.05±0.01), 12 (0.04±0.01), 13 (0.73±0.09), and if observing a similarity of the derived patient's differential diagnostic profile and the reference profile, and an agreement of all 13 relations of the patient's blood serum sample with the relations of the initial reference profile, a cerebral growth is diagnosed in the patient, and its morphological nature is described.

EFFECT: high accuracy and information value of both the presence and type of the cerebral growth, and its morphological nature.

14 dwg